These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18855988)

  • 1. Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis.
    Arase Y; Suzuki F; Suzuki Y; Akuta N; Kobayashi M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Hirakawa M; Saito S; Ikeda K; Kumada H
    World J Gastroenterol; 2008 Oct; 14(38):5880-6. PubMed ID: 18855988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cumulative incidence of and predictive factors for lung cancer in IPF.
    Ozawa Y; Suda T; Naito T; Enomoto N; Hashimoto D; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Chida K
    Respirology; 2009 Jul; 14(5):723-8. PubMed ID: 19659650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
    Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
    Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
    Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
    World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A retrospective cohort study of prognostic factors for death in patients with idiopathic pulmonary fibrosis].
    Li ZH; Peng SC; Kang J; Hou XM; Yu RJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Dec; 33(12):887-91. PubMed ID: 21211406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
    Butt AA; Yan P; Bonilla H; Abou-Samra AB; Shaikh OS; Simon TG; Chung RT; Rogal SS;
    Hepatology; 2015 Aug; 62(2):365-74. PubMed ID: 25847403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of hepatic fibrosis, cirrhosis, and mortality with cholecystectomy in patients with hepatitis C virus infection.
    Martin DJ; Weideman R; Crook T; Brown G
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):181-6. PubMed ID: 26566061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis.
    Aggarwal R; McBurney C; Schneider F; Yousem SA; Gibson KF; Lindell K; Fuhrman CR; Oddis CV
    Rheumatology (Oxford); 2017 Mar; 56(3):384-389. PubMed ID: 28082622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The predictors of mortality in IPF - Does emphysema change the prognosis?
    Tokgoz Akyıl F; Sevim T; Akman C; Aksoy E; Ağca M; Aktas O; Akyıl M
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Oct; 33(3):267-274. PubMed ID: 27758993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
    Arase Y; Kobayashi M; Suzuki F; Suzuki Y; Kawamura Y; Akuta N; Kobayashi M; Sezaki H; Saito S; Hosaka T; Ikeda K; Kumada H; Kobayashi T
    Hepatology; 2013 Mar; 57(3):964-73. PubMed ID: 22991257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study.
    Yoo H; Jeong BH; Chung MJ; Lee KS; Kwon OJ; Chung MP
    BMC Pulm Med; 2019 Aug; 19(1):149. PubMed ID: 31412851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.
    Allaire M; Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; DI Martino V; Sutton A; Letouzé E; Audureau E; Roudot-Thoraval F;
    Hepatology; 2018 Oct; 68(4):1245-1259. PubMed ID: 29663511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C.
    Arase Y; Kobayashi M; Kawamura Y; Suzuki F; Suzuki Y; Akuta N; Kobayashi M; Sezaki H; Saito S; Hosaka T; Ikeda K; Kumada H; Kobayashi T
    J Med Virol; 2014 Jan; 86(1):169-75. PubMed ID: 24155199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin.
    Preda CM; Popescu CP; Baicus C; Constantinescu I; Oproiu A; Voiosu T; Diculescu M; Negreanu L; Gheorghe L; Sporea I; Trifan A; Ceausu E; Proca D; Manuc M
    J Viral Hepat; 2018 Jul; 25(7):834-841. PubMed ID: 29397016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load.
    Sinn DH; Lee J; Goo J; Kim K; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Yoo BC; Paik SW
    Hepatology; 2015 Sep; 62(3):694-701. PubMed ID: 25963803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
    van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
    JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit.
    Álvaro-Meca A; Jiménez-Sousa MA; Boyer A; Medrano J; Reulen H; Kneib T; Resino S
    BMC Infect Dis; 2016 Mar; 16():122. PubMed ID: 26979964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.